Trial · NCT03013491
Adverse events7,505
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 7,505
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.03 mg/kg (Part A and Part A2) | 1 | 2 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.1 mg/kg (Part A and Part A2) | 0 | 2 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.3 mg/kg (Part A and Part A2) | 0 | 8 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 1 mg/kg (Part A and Part A2) | 1 | 9 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 3 mg/kg (Part A and Part A2) | 4 | 13 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10 mg/kg (Part A and Part A2) | 4 | 16 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 30 mg/kg (Part A and Part A2) | 2 | 3 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 1 | 6 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 1 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 3 | 8 | 3 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10 mg/kg + Ipilimumab 6 mg/kg (Part B1) | 0 | 6 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10 mg/kg + Ipilimumab 10 mg/kg (Part B1) | 1 | 1 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 3 mg/kg + Ipilimumab 3 mg/kg (Part B2) | 2 | 6 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10 mg/kg + Ipilimumab 3 mg/kg (Part B2) | 0 | 1 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 1 mg/kg + Vemurafenib 960 mg (Part C) | 2 | 3 | 6 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 3 mg/kg + Vemurafenib 960 mg (Part C) | 2 | 6 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10 mg/kg + Vemurafenib 960 mg (Part C) | 1 | 2 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10mg/kg Expansion (Part D) | 24 | 98 | 40 |
| other | Leukocytosis | Blood and lymphatic system disorders | CX-072 0.03 mg/kg (Part A and Part A2) | 0 | 2 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03013491/events